A roundup of manufacturing news from Valneva and Alvogen. Highlights below. 

* Valenva in $33-M Contract with US Gov’t for Encephalitis Vaccine Supply
* Alvogen Issues Voluntary Recall of One Lot of Fentanyl Transdermal Patch 

Valenva in $33-M Contract with US Gov’t for Encephalitis Vaccine Supply 
Valneva, a specialty vaccine company, has announced the signing of a new $32.8-million contract with the US Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, Ixiaro. Under this new one-year contract, the DoD will buy a minimum of $32.8 million worth of vaccines and has the possibility to purchase additional doses during the coming twelve months (as reported on January 30, 2025). Deliveries of Ixiaro doses continued in 2024 under a supply contract signed in September 2023. The new contract will begin immediately (as reported on January 30, 2025). In the US, Valneva markets and distributes Ixiaro directly to the military and private travel market. 

Source: Valneva 

Alvogen Issues Voluntary Recall of One Lot of Fentanyl Transdermal Patch 
Alvogen, a Morristown, New Jersey-based bio/pharmaceutical company, is voluntarily recalling one lot of fentanyl transdermal system 25 mcg/h transdermal patches to the consumer level due to the potential that patches could be multi-stacked, adhered one on top of the other, in a single-product pouch. The transdermal system is manufactured by a third-party manufacturer and distributed by Alvogen as a private-label distributor. 

The product is indicated for the management of severe and persistent pain in opioid-tolerant patients, that requires an extended treatment period with a daily opioid analgesic in opioid-tolerant patients, and for which alternative treatment options are inadequate. It is packaged in primary cartons of five individually wrapped and labeled pouches. 

Source: Alvogen